A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC).

培美曲塞 卡铂 医学 临床终点 安慰剂 内科学 中期分析 中止 肿瘤科 无进展生存期 化疗 代理终结点 临床试验 顺铂 病理 替代医学
作者
Caicun Zhou,Ziping Wang,Meili Sun,Lejie Cao,Zhiyong Ma,Rong Wu,Yan Yu,Wenxiu Yao,Si Sun,Jianhua Chen,Wu Zhuang,Jiuwei Cui,Xueqin Chen,You Lu,Chunhong Hu,Jingru Wang,Rumei Chen,Mengmeng Qin,Hao Chen,Jason Yang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 9027-9027 被引量:6
标识
DOI:10.1200/jco.2022.40.16_suppl.9027
摘要

9027 Background: GEMSTONE-302, a randomized, double-blind, phase 3 study, previously met its primary endpoint and demonstrated statistically significant and clinically meaningful prolongation of progression-free survival (PFS) with suge+chemo vs placebo+chemo as a 1L treatment in pts with metastatic NSCLC. PFS benefit was observed in both squamous (sq) and non-squamous (nsq) NSCLC, regardless of PD-L1 expression levels. Here we report the data from a protocol pre-specified interim OS analysis. Methods: Pts with systemic treatment-naïve stage IV NSCLC, measurable disease per RECIST v1.1, ECOG PS 0-1, and no known EGFR, ALK, ROS1 and RET alterations were randomized 2:1 to receive suge (1200 mg, IV) or placebo plus chemo (sq-NSCLC: carboplatin+paclitaxel; nsq-NSCLC: carboplatin+pemetrexed) every 3 weeks for up to 4 cycles, followed by maintenance therapy (sq-NSCLC: suge/placebo; nsq-NSCLC: suge/placebo+pemetrexed) for up to 35 cycles. The primary endpoint was investigator assessed PFS (INV-PFS). Key secondary endpoints included OS, INV-PFS in pts with tumor PD-L1 expression ≥1%, and ORR. Pts in the placebo group could cross over to receive suge monotherapy upon disease progression. Results: As of 22 Nov 2021, among all 479 enrolled pts, 51 (15.9%) and 7 (4.4%), respectively, remained on treatment with suge+chemo or placebo+chemo. The median follow-up was 25.4 and 24.9 months, respectively. Following treatment discontinuation, 17.8% and 43.4% of the pts, respectively, received cross-over suge or other non-study anti-PD-(L)1-containing therapies. Median OS was 25.4 months in suge+chemo group vs 16.9 months in placebo+chemo group (HR = 0.65 [95%CI, 0.50-0.84], p = 0.0008), and 2-year OS rate was 51.7% vs 35.6%. OS benefits were observed across all subgroups including different tumor histologies (sq: HR = 0.56; nsq: HR = 0.72) and PD-L1 expression levels (≥1%: HR = 0.64; < 1%: HR = 0.66). In the intent-to-treat population, median PFS was 9.0 months with suge+chemo vs 4.9 months with placebo+chemo (HR = 0.49 [0.40-0.61]), and 2-year PFS rate was 20.8% vs 7.3%. In pts with PD-L1≥1%, the median PFS was 10.9 vs 4.9 months (HR = 0.48 [0.36-0.63], p < 0.0001). ORR was 63.4% vs 40.3% (p < 0.0001). Among pts with baseline brain metastases, suge+chemo improved their OS (HR = 0.45) and intracranial INV-PFS (post-hoc analysis, HR = 0.33) vs placebo+chemo. Safety profile was consistent with previously reported results. Conclusions: Suge plus chemo demonstrated statistically significant and clinically meaningful OS improvement compared with placebo plus chemo, irrespective of tumor histology or PD-L1 expression levels, in pts with newly diagnosed metastatic NSCLC, offering a new 1L treatment option for this group of pts. Clinical trial information: NCT03789604.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐的应助被楼马采纳,获得10
刚刚
Jasper的应助被JoyceWu采纳,获得10
刚刚
张先生完成签到 ,获得积分20
刚刚
zzyh完成签到,获得积分10
刚刚
1秒前
小蘑菇的应助被竹园采纳,获得10
1秒前
酷波er的应助被一只金鱼采纳,获得10
1秒前
爱笑麦丽素完成签到 ,获得积分10
2秒前
2秒前
栗江南发布了新的文献求助10
3秒前
zsm完成签到 ,获得积分10
3秒前
乐观发夹的应助被陈泽采纳,获得10
4秒前
wz发布了新的文献求助10
4秒前
4秒前
wanci的应助被今天吃什么采纳,获得10
5秒前
岚婘发布了新的文献求助20
5秒前
找文献的小赖完成签到,获得积分10
5秒前
fcwo完成签到,获得积分10
5秒前
Lemonhead的应助被辛酸有很多种采纳,获得10
5秒前
6秒前
6秒前
6秒前
小蘑菇的应助被kinlo97采纳,获得10
7秒前
7秒前
小巧如音发布了新的文献求助20
7秒前
师德完成签到 ,获得积分10
7秒前
无情妙菡完成签到,获得积分10
8秒前
李健的小迷弟的应助被dyq采纳,获得10
8秒前
乐乐的应助被璐璇采纳,获得10
8秒前
8秒前
8秒前
9秒前
qqqqqqqqqqq完成签到,获得积分10
9秒前
lzd发布了新的文献求助10
9秒前
10秒前
grawlix完成签到,获得积分10
10秒前
星郁白完成签到,获得积分10
10秒前
Shep_LAB发布了新的文献求助10
10秒前
共享精神的应助被蒲公英采纳,获得10
10秒前
周震洋完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157506
求助须知:如何正确求助?哪些是违规求助? 9553394
关于积分的说明 21714153
捐赠科研通 7746572
什么是DOI,文献DOI怎么找? 3426779
关于科研通互助平台的介绍 2551516
邀请新用户注册赠送积分活动 2470722